5 results about "Human sequence" patented technology

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The present application relates to a tumor risk prediction method and device based on cfDNA nucleosome fingerprint, belonging to the technical field of in vitro diagnosis. Among them, the method comprises: obtaining whole genome sequencing data of plasma or serum cfDNA; the whole genome sequencing data is subjected to quality control processing to remove non-human sequences to obtain human cfDNA sequencing fragments; the human cfDNA sequencing fragments are aligned to the human reference genome to obtain the genomic coordinates of each fragment and the coverage information thereof on the reference genome; based on the whole genome coverage signal, the enrichment region identification algorithm is used to determine the nucleosome positioning boundary, and the peak signal strength is taken as the nucleosome positioning intensity score; the nucleosome positioning intensity score is input into the tumor risk prediction model which has been trained, and the prediction risk probability of the subject suffering from tumor is output. Greatly improve the accuracy of noninvasive screening tumor prediction tumor risk, and the detection cost is low and the cycle is short.

The invention provides a recombinant human collagen type II COLII-23k. The amino acid sequence of the recombinant human collagen type II COLII-23k is as shown in SEQ ID NO. 1. The invention also provides a pichia pastoris engineering bacterium for expressing the collagen COLII-23k, the engineering bacterium comprises a gene for coding the COLII-23k, and the coding gene is connected to a pichia pastoris expression vector in a seamless cloning manner. Meanwhile, the invention also provides an application of the collagen COLII-23k. The invention has the advantages that the active fragment COLII-23k of the human collagen type II provided by the invention is a complete human sequence, does not have redundant amino acid, and has excellent hemostatic activity and skin cell proliferation, adhesion and migration promotion functions; pichia pastoris engineering bacteria for expressing the protein are constructed through seamless cloning, the expression quantity is high, and industrial production is easy; and the collagen is wide in application scene, and can meet the requirements of multiple fields such as hemostasis, wound repair and medical beauty.